Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications

Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications

Patients with non-small cell lung cancer (NSCLC) develop bone metastasis (BoM) in more than 50% of cases during the course of the disease. This metastatic site can lead to the development of skeletal related events (SREs), such as severe pain, pathological fractures, spinal compression, and hypercal...

Full description

Bibliographic Details
Main Authors: Alessandro Del Conte, Elisa De Carlo, Elisa Bertoli, Brigida Stanzione, Alberto Revelant, Manuela Bertola, Michele Spina, Alessandra Bearz
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:International Journal of Molecular Sciences
Subjects:
bone metastasis
immunotherapy
immune checkpoint inhibitors
microenvironment
non-small cell lung cancer (NSCLC)
Online Access:https://www.mdpi.com/1422-0067/23/12/6832

Internet

https://www.mdpi.com/1422-0067/23/12/6832

Similar Items